The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent.
Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...
The approval is based on results of the AcT trial, where tenecteplase was comparable to alteplase for safety and efficacy.
The 5-second intravenous bolus offers faster, simpler administration than Activase. (HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or ...
TNKase is delivered as a single five-second intravenous (IV) bolus, a faster and simpler administration compared to the standard-of-care, Activase, which is administered as an IV bolus followed by ...
11d
News-Medical.Net on MSNFDA approves Genentech’s TNKase® in acute ischemic stroke in adultsGenentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase® (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment ...
The FDA has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke (AIS) in ...
Tenecteplase is administered as a single, 5-second intravenous bolus, providing a faster and simpler option compared to the ...
TNKase will be available for the treatment of acute ischemic stroke in adults, joining the Roche subsidiary’s Activase (alteplase) on the market – also approved for the same indication.
TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...
Genentech, a member of the Roche Group, announced that the FDA has approved the company’s TNKase (tenecteplase) thrombolytic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results